TRPX Therapix Biosciences Ltd.

0.5
-0.11  -18%
Previous Close 0.61
Open 0.61
Price To Book -5
Market Cap 3,610,572
Shares 7,219,700
Volume 358,164
Short Ratio
Av. Daily Volume 231,253
Stock charts supplied by TradingView

NewsSee all news

  1. Therapix Biosciences Ltd. Receives Nasdaq Notification Regarding Minimum Bid Requirements

    TEL AVIV, Israel, Feb. 27, 2020 /PRNewswire/ -- Therapix Biosciences Ltd. (NASDAQ:TRPX), a specialty, clinical-stage pharmaceutical company focusing on the development of cannabinoid-based treatments announced today that

  2. Nasdaq Hearings Panel Grants Therapix Biosciences Extension to Regain Compliance With Listing Requirements

    TEL AVIV, Israel, Feb. 6, 2020 /PRNewswire/ -- Therapix Biosciences Ltd. (NASDAQ:TRPX), a specialty, clinical-stage pharmaceutical company focusing on the development of cannabinoid-based treatments announced today that

  3. Therapix Biosciences Announces Pricing of $1,250,000 Registered Direct Offering

    TEL AVIV, Israel, Dec. 4, 2019 /PRNewswire/ -- Therapix Biosciences Ltd. ("Therapix" or the "Company") (NASDAQ:TRPX), a specialty, clinical-stage pharmaceutical company focusing on the development of

  4. Therapix Biosciences Announces the Continued Development of THX-210 ("RESPECTRUM") Cannabinoids Based Treatment for Autism Spectrum Disorder

    TEL AVIV, Israel, Dec. 2, 2019 /PRNewswire/ -- Therapix Biosciences Ltd. ("Therapix" or the "Company") (NASDAQ:TRPX), a specialty, clinical-stage pharmaceutical company focusing on the development of

  5. SOL Global Reports Second Quarter Results for the Three and Six-Month Period Ending September 30, 2019

    Invested Amount in Key Assets Including Heavenly Rx And Florida Cannabis Operations SOL Global Investments Corp. ("SOL Global" or "Company") (CSE:SOL) (OTCPK: SOLCF) (Frankfurt: 9SB) released its financial results as

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 2a trial likely to be completed 2H 2020 (Germany).
THX-110
Tourette Syndrome
Phase 2a trial ongoing.
THX-110
Chronic pain
Phase 2a top-line data met primary endpoint - November 13, 2019.
THX-110
Obstructive Sleep Apnea (OSA)

Latest News

  1. Therapix Biosciences Ltd. Receives Nasdaq Notification Regarding Minimum Bid Requirements

    TEL AVIV, Israel, Feb. 27, 2020 /PRNewswire/ -- Therapix Biosciences Ltd. (NASDAQ:TRPX), a specialty, clinical-stage pharmaceutical company focusing on the development of cannabinoid-based treatments announced today that

  2. Nasdaq Hearings Panel Grants Therapix Biosciences Extension to Regain Compliance With Listing Requirements

    TEL AVIV, Israel, Feb. 6, 2020 /PRNewswire/ -- Therapix Biosciences Ltd. (NASDAQ:TRPX), a specialty, clinical-stage pharmaceutical company focusing on the development of cannabinoid-based treatments announced today that

  3. Therapix Biosciences Announces Pricing of $1,250,000 Registered Direct Offering

    TEL AVIV, Israel, Dec. 4, 2019 /PRNewswire/ -- Therapix Biosciences Ltd. ("Therapix" or the "Company") (NASDAQ:TRPX), a specialty, clinical-stage pharmaceutical company focusing on the development of

  4. Therapix Biosciences Announces the Continued Development of THX-210 ("RESPECTRUM") Cannabinoids Based Treatment for Autism Spectrum Disorder

    TEL AVIV, Israel, Dec. 2, 2019 /PRNewswire/ -- Therapix Biosciences Ltd. ("Therapix" or the "Company") (NASDAQ:TRPX), a specialty, clinical-stage pharmaceutical company focusing on the development of

  5. SOL Global Reports Second Quarter Results for the Three and Six-Month Period Ending September 30, 2019

    Invested Amount in Key Assets Including Heavenly Rx And Florida Cannabis Operations SOL Global Investments Corp. ("SOL Global" or "Company") (CSE:SOL) (OTCPK: SOLCF) (Frankfurt: 9SB) released its financial results as

  6. Therapix Biosciences Announces Receipt of Notice of Delisting From Nasdaq and Intention to Appeal

    TEL AVIV, Israel, Nov. 20, 2019 /PRNewswire/ -- Therapix Biosciences Ltd. ("Therapix" or the "Company") (NASDAQ:TRPX), a specialty, clinical-stage pharmaceutical company focusing on the development of

  7. SOL Global Portfolio Company Heavenly Rx, Ltd. Enters Into MOU for Business Combination with Therapix Biosciences

     Parties to Move Towards Definitive Agreements to Merge Heavenly Rx With Cutting Edge Cannabinoid Pharmaceutical Company Heavenly Rx Nominates former Kimberly Clark Chief Marketing Officer and Kellogg's former Chief

  8. Therapix Biosciences Enters Into MOU for Business Combination With Heavenly Rx, Ltd.

    TEL AVIV, Israel, Nov. 18, 2019 Therapix Biosciences Ltd. ("Therapix" or the "Company") (NASDAQ:TRPX), announced today that it entered into a memorandum of understanding ("MOU") with Heavenly Rx,

  9. Therapix Biosciences Announces Positive Topline Results From Phase IIa Clinical Trial of THX-110 for Obstructive Sleep Apnea Program

    TEL AVIV, Israel, Nov. 13, 2019 /PRNewswire/ -- Therapix Biosciences Ltd. ("Therapix" or the "Company") (NASDAQ:TRPX), a specialty, clinical-stage pharmaceutical company focusing on the development of

  10. Therapix Biosciences and Destiny Biosciences Global Corp. Mutually Decide to Discontinue Negotiations on Planned Merger

    TEL AVIV, Israel, Nov. 7, 2019 /PRNewswire/ -- Therapix Biosciences Ltd. ("Therapix" or the "Company") (NASDAQ:TRPX), a specialty, clinical-stage pharmaceutical company focusing on the development of

  11. Therapix Biosciences Announces Positive Data From Recent Pre-clinical Study for New Drug Candidate THX-210

    TEL AVIV, Israel, Oct. 15, 2019 /PRNewswire/ -- Therapix Biosciences Ltd. (NASDAQ:TRPX), a specialty, clinical-stage pharmaceutical company focusing on the development of cannabinoid-based treatments, announced today

  12. Therapix Biosciences Provides Update on Planned Merger With Destiny Biosciences Global Corp.

    TEL AVIV, Israel, Oct. 10, 2019 /PRNewswire/ -- Therapix Biosciences Ltd. ("Therapix" or the "Company") (NASDAQ:TRPX), a specialty, clinical-stage pharmaceutical company focusing on the development of

  13. Nasdaq Grants Therapix Biosciences Extension to Comply With Stockholders' Equity Requirement

    TEL AVIV, Israel, Aug. 27, 2019 /PRNewswire/ -- Therapix Biosciences Ltd. ("Therapix" or the "Company") (NASDAQ:TRPX), a specialty, clinical-stage pharmaceutical company focusing on the development of